Anti-RNase L – Purified in vivo PLATINUM™ Functional Grade

Based on the search results provided, there is limited information about in vivo applications of clone 2E9 specifically in mice. The search results primarily describe various antibodies with the clone designation 2E9, but most are designed for different purposes or species.

The most relevant antibody for potential mouse in vivo applications appears to be clone 9E9 (not 2E9), which is an anti-mouse CD16.2 antibody. Clone 9E9 is specifically designed as a monoclonal antibody used in in vivo mouse studies to block and investigate the function of mouse CD16.2 (FcγRIV), a receptor involved in immune responses. This antibody is available in functional grade formats suitable for in vivo research.

The clone 2E9 antibodies described in the search results target different proteins and species:

• Anti-RNase L (clone 2E9) is a mouse monoclonal antibody that detects Ribonuclease L in human cells, evaluated primarily through immunohistochemistry in human tissue sections

• Anti-SLA Class II DR (clone 2E9/13) is a mouse monoclonal antibody specific for pig (porcine) SLA molecules, not designed for mouse applications

• Anti-Amyloid beta A4 protein (clone 2E9) is a rat monoclonal antibody that targets amyloid beta in mouse and human samples, but the search results only mention validation for in vitro techniques like immunofluorescence, immunoprecipitation, and Western blotting

The search results explicitly state that these antibodies are intended for research use only and not for therapeutic applications. Without specific documentation of clone 2E9 being used in mouse in vivo studies, it appears this clone designation primarily represents antibodies validated for in vitro applications or for use in other species.

Commonly used antibodies or proteins employed together with 2E9 in the literature depend on the specific context, as “2E9” is an antibody name that appears in association with several different targets (e.g., amyloid-beta, tau, N-terminal ubiquitin peptides, fuc-PSA, etc.). Most studies that use 2E9 also deploy secondary antibodies, detection controls, or antibodies against related protein targets:

• For Amyloid-beta (Aβ) detection (Anti-beta Amyloid antibody [2E9]):

  • Commonly paired with other Alzheimer’s disease markers such as anti-tau antibodies (e.g., Tau 2E9, AT8, PHF-1), and anti-APP (amyloid precursor protein) antibodies.
  • Secondary antibodies: HRP-, biotin-, or fluorescent dye-conjugated goat, donkey, or rabbit secondary antibodies are routinely used for visualization.
  • Controls: Non-immune IgG as negative control, and hematoxylin or DAPI as nuclear counterstain.

• For Tau detection (Tau Antibody 2E9):

  • Used in combination with anti-MAP2 (Microtubule-Associated Protein 2) antibodies to distinguish dendrites from axons.
  • Also paired with secondary antibodies conjugated with enzymes (HRP, AP) or fluorophores for detection.
  • Sometimes used with anti-GAP43 or anti-MARCKS for comparison with other neuronal proteins.

• For ELISA-based sandwich assays (such as fucosylated PSA detection with 2E9):

  • 2E9 serves as one antibody in a sandwich ELISA, commonly combined with a capture antibody such as a rabbit polyclonal anti-total PSA antibody.
  • Proteins like biotinylated PSA, haptoglobin, AFP, and transferrin are included as specificity controls or for comparative assay development.

• For ubiquitin/peptide detection (2E9 as an anti-N-terminal ubiquitin peptide antibody):

  • Used alongside other anti-peptide antibodies such as 1C7 and 2B12, which target similar or overlapping epitopes for comparative binding and functional studies.

• General immunoassay workflows:

  • Secondary antibodies conjugated to HRP, AP, biotin, or fluorescent dyes are universally employed for detection.
  • Proteins A, G, and L may be used to capture and purify IgG or related antibodies from mixed samples.

Summary Table: Associated Antibodies/Proteins Commonly Used with 2E9

In all cases, the selection of additional antibodies or proteins is driven by experimental needs, such as detection, specificity, and controls. If you can specify which 2E9 antibody or system you are interested in, a more targeted list can be provided.

Clones with the designation "2E9" are mentioned in various scientific contexts, targeting different antigens. Here are some key findings from the citations involving clone 2E9 antibodies:

1. Mouse Anti-Pig SLA Class II DR Antibody (2E9/13):

   • This monoclonal antibody recognizes SLA Class II DR molecules expressed on B cells, antigen-presenting cells, and certain subsets of T cells.
   • It reacts with lymphocytes from all outbred and miniature pigs tested, suggesting recognition of a monomorphic determinant.
   • The antibody can inhibit mixed lymphocyte reactions and T cell stimulation induced by certain pathogens.

2. Anti-EGFR Antibody (2E9):

   • This mouse monoclonal antibody targets the epidermal growth factor receptor (EGFR) and is suitable for flow cytometry, ICC/IF in human samples.
   • It has been cited in several publications, though specific applications are not detailed.

3. Tau Antibody (2E9):

   • This antibody targets tau protein, which is associated with neurodegenerative diseases.
   • It has been used in Western Blot and immunocytochemistry to study tau expression in neuronal tissues.
   • The antibody is reported to stain perikarya, dendrites, and axons in neurons.

4. Alpha-1 Antitrypsin Antibody (2E9):

   • There is no specific mention of this antibody in the provided results, but the designation "2E9" is used for other targets like fuc-PSA in different contexts.

These clones are used in different fields ranging from immunology to neurobiology, each targeting specific antigens and contributing to respective research areas.

Dosing regimens of clone 2e9 (also referred to as clone 2E9/13 in published antibody catalogues) are not consistently detailed across mouse model literature, as this antibody is primarily used for studies involving pig SLA Class II DR antigens and not widely adopted for murine targets. When dosing monoclonal antibodies in mouse models, the general approach is to administer:

• Fixed doses (typically 100–250 μg per mouse)
• Intraperitoneal injections
• 1–3 times per week depending on the antibody target and intended functional outcome (e.g. depletion, agonism, or blockade).

However, specific published dosing regimens for clone 2e9 in different mouse models could not be found in current antibody dosing guides or literature. This likely stems from its specificity for pig SLA rather than mouse antigens, meaning standard murine depletion or immune modulation regimens do not readily apply.

For antibodies in mouse models, dosing may vary based on:

• Target antigen (murine vs. non-murine targets)
• Application (e.g. depletion, functional inhibition, immunohistology)
• Mouse strain (immunocompetent vs. immunodeficient, tumor vs. infection models)
• Antibody isotype and mechanism (IgG subtype, Fc-dependent function).

When translating dosing between models:

• Guidelines recommend initially using fixed dosing schedules in first-in-animal studies, adjusting based on pharmacokinetics, safety, and efficacy.
• If body weight significantly affects clearance or distribution, body weight-based dosing may sometimes be justified, but for many mAbs, fixed dosing is flexible and preferred.

Key context

• If clone 2e9 is to be used in mouse models expressing pig SLA antigens (e.g., transgenic mice or xenografts), one could extrapolate dosing from similar antibody regimens: starting at 100–250 μg per injection, intraperitoneally, 2–3 times per week. Adjustments should be made based on preliminary pharmacokinetics and observed biological activity.

• For applications outside depletion (e.g., inhibition of cell stimulation or reaction assays, as reported for clone 2E9/13 in pig cells), titration according to in vivo responses in each mouse model is necessary due to likely differences in immune interactions.

There is currently no evidence for standardized dosing regimens of clone 2e9 across mouse models, likely because its primary specificity is for porcine antigens. Any application in mice would follow general monoclonal antibody dosing guidelines, beginning with cautious titration and adjustment based on pilot data.